MapLight Therapeutics, Inc.(MPLT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MPLT MapLight Therapeutics, Inc.

盘后交易 10-28 18:53:16 EDT

7.98

-0.19

-2.33%

盘后7.93

-0.05-0.64%

16:46 EDT

最高8.14	最低7.81	成交量36.59万
今开8.09	昨收8.17	日振幅3.98%
总市值4.43亿	流通市值1.53亿	总股本5,558万
成交额292.44万	换手率1.90%	流通股本1,923万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"MPLT","market":"US","secType":"STK","nameCN":"MapLight Therapeutics, Inc.","latestPrice":7.98,"timestamp":1793217600000,"preClose":8.17,"halted":0,"volume":365932,"hourTrading":{"tag":"盘后","latestPrice":7.9286,"preClose":7.98,"latestTime":"16:46 EDT","volume":3826,"amount":30514.878986,"timestamp":1793220412396,"change":-0.0514,"changeRate":-0.006441,"amplitude":0.006441},"delay":0,"changeRate":-0.023255813953488313,"floatShares":19234500,"shares":55575700,"eps":-5.058,"marketStatus":"盘后交易","change":-0.19,"latestTime":"10-28 18:53:16 EDT","open":8.09,"high":8.135,"low":7.81,"amount":2924359.3370432,"amplitude":0.03978,"askPrice":12.48,"askSize":100,"bidPrice":7.92,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-5.058,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1793232000000},"marketStatusCode":4,"adr":0,"listingDate":1761537600000,"exchange":"NASDAQ","adjPreClose":8.17,"preHourTrading":{"tag":"盘前","latestPrice":7.91,"preClose":8.17,"latestTime":"06:18 EDT","volume":4,"amount":31.64,"timestamp":1793182737573,"change":-0.26,"changeRate":-0.031824,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":7.9286,"preClose":7.98,"latestTime":"16:46 EDT","volume":3826,"amount":30514.878986,"timestamp":1793220412396,"change":-0.0514,"changeRate":-0.006441,"amplitude":0.006441},"volumeRatio":1.118067,"impliedVol":1.0235,"impliedVolPercentile":0.4151},"requestUrl":"/m/hq/s/MPLT","defaultTab":"news","newsList":[{"id":"1142889247","title":"MapLight Therapeutics提交SEC文件：招股说明书涵盖售股股东转售最多13,181,055股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1142889247","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142889247?lang=zh_cn&edition=full","pubTime":"2026-09-10 05:30","pubTimestamp":1788989410,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics向美国证券交易委员会（SEC）提交了一份招股说明书。该文件显示，公司计划允许售股股东转售最多达13,181,055股普通股。这一举措标志着公司在股权流通方面迈出了重要一步。此次转售安排由相关售股股东主导，MapLight Therapeutics本身并未在此次交易中发行新股。招股说明书的提交，为现有股东提供了在公开市场上出售所持股份的途径。这一动作也反映了公司对市场流动性的关注，以及对股东权益的重视。投资者将密切关注这一潜在股票供应对市场供需平衡的影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114412720","title":"MapLight Therapeutics 盘前暴跌55.7%：精神分裂症药物中期试验结果不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1114412720","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114412720?lang=zh_cn&edition=full","pubTime":"2026-07-27 20:13","pubTimestamp":1785154388,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics 的股价在盘前交易中遭遇重挫，跌幅高达55.7%。这一剧烈波动源于公司公布了其针对精神分裂症药物的中期试验结果。市场对此次披露的数据反应极为负面，投资者信心受挫，导致股价在开盘前便大幅跳水。该公司正面临严峻考验，后续发展引人关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109776896","title":"MapLight Therapeutics 每日一次330/6毫克剂量未能达到主要终点统计显著性","url":"https://stock-news.laohu8.com/highlight/detail?id=1109776896","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109776896?lang=zh_cn&edition=full","pubTime":"2026-07-27 19:18","pubTimestamp":1785151139,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics Inc. 宣布，其每日一次（QD）330/6毫克剂量的治疗方案，在主要终点指标上未能实现统计学显著性。这一结果意味着该剂量方案在该项研究中并未展现出预期的疗效优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137673591","title":"MapLight Therapeutics在2期试验中：210/3毫克BID剂量于第5周显著改善PANSS评分","url":"https://stock-news.laohu8.com/highlight/detail?id=1137673591","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137673591?lang=zh_cn&edition=full","pubTime":"2026-07-27 19:03","pubTimestamp":1785150236,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics的研究取得新进展。其210/3毫克BID剂量的药物，在2期临床试验中，展现出显著成效。该试验在第5周时，患者的PANSS评分获得了明显改善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154497493","title":"MapLight Therapeutics 公布精神分裂症药物 Ml-007C-Ma 二期 Zephyr 试验积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1154497493","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154497493?lang=zh_cn&edition=full","pubTime":"2026-07-27 19:02","pubTimestamp":1785150160,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics 宣布，其针对精神分裂症的在研药物 Ml-007C-Ma，在二期 Zephyr 临床试验中取得了积极的顶线结果。这一里程碑式的进展，为饱受精神分裂症困扰的患者群体带来了新的希望。该研究的详细数据，将在后续的医学会议上进一步公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193604406","title":"Maplight Therapeutics旗下Ml-007C-Ma耐受性良好，无严重或药物相关严重不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1193604406","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193604406?lang=zh_cn&edition=full","pubTime":"2026-07-27 19:02","pubTimestamp":1785150133,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics, Inc. 宣布，其研发的Ml-007C-Ma在临床试验中展现出良好的耐受性。值得注意的是，该药物在受试者中未引发任何严重不良事件，亦未出现与药物相关的严重不良反应。这一结果，无疑为后续的研发工作注入了强心剂。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100562159","title":"MapLight Therapeutics——推进额外注册性试验，与FDA启动二期尾声沟通","url":"https://stock-news.laohu8.com/highlight/detail?id=1100562159","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100562159?lang=zh_cn&edition=full","pubTime":"2026-07-27 19:02","pubTimestamp":1785150132,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics——计划启动一项额外的注册性试验，并在二期临床结束时与美国食品药品监督管理局（FDA）展开对接。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105042736","title":"Raymond James首予MapLight Therapeutics强力买入评级，目标价46美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1105042736","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105042736?lang=zh_cn&edition=full","pubTime":"2026-06-25 19:20","pubTimestamp":1782386432,"startTime":"0","endTime":"0","summary":"Raymond James 分析师近日发布研报，首次覆盖生物技术公司 MapLight Therapeutics，并给予其“强力买入”评级。报告同时为该股设定了46美元的目标价，显示出对该司未来前景的强烈信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130988345","title":"MapLight Therapeutics公司Ml-004在二期IRIS试验中总体耐受性良好，未出现严重或重度不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1130988345","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130988345?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:04","pubTimestamp":1782126257,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics公司宣布，其候选药物Ml-004在二期IRIS临床试验中表现出良好的安全性特征。试验数据显示，该药物总体耐受性良好，期间未报告任何严重或重度的不良事件。\n这一积极的安全数据为Ml-004的进一步开发奠定了重要基础。公司将继续推进相关临床研究，以评估该疗法在目标适应症中的有效性与长期安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135687202","title":"MapLight Therapeutics, Inc.声明：Setia离职无权获得任何遣散费","url":"https://stock-news.laohu8.com/highlight/detail?id=1135687202","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135687202?lang=zh_cn&edition=full","pubTime":"2026-06-19 05:07","pubTimestamp":1781816835,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics, Inc.发布声明称，根据相关协议条款，Setia先生因其离职行为，无权获得任何形式的遣散费用。公司强调，此举严格遵循了既定的雇佣合同与内部政策规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156015941","title":"MapLight Therapeutics首席财务官Vishwas Setia于2026年6月18日起即刻离职 - 美国证券交易委员会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1156015941","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156015941?lang=zh_cn&edition=full","pubTime":"2026-06-19 05:03","pubTimestamp":1781816596,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会(SEC)的文件，生物制药公司MapLight Therapeutics, Inc.宣布，其首席财务官Vishwas Setia已于2026年6月18日即刻卸任。\n该文件显示，Setia的离职自2026年6月18日起立即生效。目前，公司尚未公布其首席财务官职位的继任计划。此次人事变动通过SEC的正式文件对外披露，标志着公司管理层的一次重要调整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126953001","title":"MapLight Therapeutics宣布Zephyr二期临床试验完成入组并更新关键结果预期时间表","url":"https://stock-news.laohu8.com/highlight/detail?id=1126953001","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126953001?lang=zh_cn&edition=full","pubTime":"2026-05-01 19:00","pubTimestamp":1777633228,"startTime":"0","endTime":"0","summary":"生物制药公司MapLight Therapeutics近日宣布，其针对精神神经疾病的Zephyr二期临床试验已完成患者入组工作。该公司同时更新了这项研究的关键顶线结果预计公布时间。\n此次临床试验的顺利推进标志着MapLight Therapeutics在精神神经疾病治疗领域取得重要进展。公司表示将按计划推进后续数据整理与分析工作，并及时向市场披露相关研究成果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.maplightrx.com","stockEarnings":[{"period":"1week","weight":-0.0085},{"period":"1month","weight":-0.2189},{"period":"3month","weight":-0.4561},{"period":"6month","weight":-0.7436},{"period":"1year","weight":-0.5545},{"period":"ytd","weight":-0.5349}],"compareEarnings":[{"period":"1week","weight":0.0008},{"period":"1month","weight":-0.0022},{"period":"3month","weight":0.0551},{"period":"6month","weight":0.071},{"period":"1year","weight":0.1232},{"period":"ytd","weight":0.1287}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"MapLight Therapeutics, Inc.于2018年11月根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司，专注于开发中枢神经系统疾病的治疗方法。其主要候选药物ML-007C-MA是一种用于治疗精神分裂症和阿尔茨海默病精神病的固定剂量复方毒蕈碱激动剂，目前处于2期试验阶段。该公司还在开发用于治疗自闭症谱系障碍社交沟通障碍的ML-004。","exchange":"NASDAQ","name":"MapLight Therapeutics, Inc.","nameEN":"MapLight Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MapLight Therapeutics, Inc.(MPLT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供MapLight Therapeutics, Inc.(MPLT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"MapLight Therapeutics, Inc.,MPLT,MapLight Therapeutics, Inc.股票,MapLight Therapeutics, Inc.股票老虎,MapLight Therapeutics, Inc.股票老虎国际,MapLight Therapeutics, Inc.行情,MapLight Therapeutics, Inc.股票行情,MapLight Therapeutics, Inc.股价,MapLight Therapeutics, Inc.股市,MapLight Therapeutics, Inc.股票价格,MapLight Therapeutics, Inc.股票交易,MapLight Therapeutics, Inc.股票购买,MapLight Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MapLight Therapeutics, Inc.(MPLT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供MapLight Therapeutics, Inc.(MPLT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}